Please try another search
Canaccord Genuity analyst John Newman maintained a Buy rating on Seres Therapeutics (NASDAQ:MCRB) on Tuesday, setting a price target of $42, which is approximately 95.53% above the present share price of $21.48.
Newman expects Seres Therapeutics to post earnings per share (EPS) of -$0.19 for the second quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Seres Therapeutics, with an average price target of $38.5.
The analysts price targets range from a high of $46 to a low of $30.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $17.56 million and a net profit of -$17.9 million. The company's market cap is $1.97 billion.
According to TipRanks.com, Canaccord Genuity analyst John Newman is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 16.0% and a 43.98% success rate.
Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for reviewWe've noticed you're using an ad blocker
We spend millions of dollars each year so you can access, for FREE, the highest quality real-time quotes and charts. This is made possible only thanks to the advertising on our site.
To continue using Investing.com, please allow this domain on your ad blocker.
Allow this domain
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.